NEW YORK, NY / ACCESSWIRE / July 11, 2017 / Hemispherx Biopharma, Inc.'s shares saw a modest pop in share price yesterday after the company released an announcement about its Ampligen candidate that is being used as an immuno-oncology therapy in an Early Access Program (EAP) on 12 pancreatic patients. Shares of Alnylam Pharmaceuticals saw a drop despite also having positive news about its own Phase III study for fitusiran, an investigational RNA interference (RNAi) therapeutic being that is being developed for the treatment of rare bleeding disorders such as hemophilia.

RDI Initiates Coverage on:

Alnylam Pharmaceuticals, Inc.
https://ub.rdinvesting.com/news/?ticker=ALNY

Hemispherx Biopharma, Inc.
https://ub.rdinvesting.com/news/?ticker=HEB

Alnylam Pharmaceuticals, Inc.'s shares closed down 5.55% yesterday on trading volume almost twice as big as usual. Despite the losses, the company actually had some pretty good news on Monday. Alnylam announced with Sanofi's SNY, that the companies have begun phase III ATLAS study for fitusiran, an investigational RNA interference (RNAi) therapeutic that is being developed for the treatment of rare bleeding disorders such as hemophilia. The study will be assessing the safety and efficacy of the therapeutic in three separate trials. The trials will include patients with Hemophilia A and B with or without inhibitors as well as patients receiving prophylactic therapy. The studies ATLAS-INH and ATLAS-A/B will have patients with hemophilia A or B with inhibitors receiving prior on-demand therapy. Both studies will last nine months. The last study called ATLAS-PPX will have around 100 patients that have hemophilia A or B with or without inhibitors receiving prophylaxis therapy as prior standard of care. The top-line data from the three trials are expected in mid-to-late 2019.

Access RDI's Alnylam Pharmaceuticals, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=ALNY

Hemispherx Biopharma, Inc.'s shares closed up a modest 0.97% on Monday on tremendous volume compared to usual. The stock traded roughly 7.2 million shares compared to an average of just around 151,000 shares. The advanced specialty pharmaceutical company released an update announcing that 12 pancreatic patients are currently undergoing treatment with single-agent Ampligen immuno-oncology therapy in an Early Access Program (EAP) managed by Amsterdam-based myTomorrows. Eight of the patients in the program with metastatic disease have been on the drug for 12 weeks or longer. The other four patients entered the program more recently in the last several weeks with earlier stage disease. CEO Thomas K. Equels commented, "Ampligen has been shown in numerous earlier studies to possess both tumor-killing and immuno-modulating activity, the two characteristics that form the basis of immuno-oncology therapy. This is developing into one of the fastest growing and promising forms of cancer treatment."

The company is planning for cancer trials of the drug in the U.S.

Access RDI's Hemispherx Biopharma, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=HEB

Our Actionable Research on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Hemispherx Biopharma, Inc. (NYSE: HEB) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com